Crossmark

Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

Crossref DOI link: https://doi.org/10.1136/rmdopen-2022-002323

Published Online: 2022-05-19

Published Print: 2022-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Fagni, Filippo https://orcid.org/0000-0002-6122-0774
Schmidt, Katja

Bohr, Daniela

Valor-Méndez, Larissa https://orcid.org/0000-0002-4872-3502
Hartmann, Fabian

Tascilar, Koray

Manger, Karin

Manger, Bernhard https://orcid.org/0000-0003-2375-0069
Kleyer, Arnd https://orcid.org/0000-0002-2026-7728
Simon, David https://orcid.org/0000-0001-8310-7820
Schett, Georg

Harrer, Thomas
License Information

License valid from 2022-05-18